Hormonal
Once-weekly subcutaneous semaglutide 2.4 mg significantly reduces systemic inflammation, measured by C-reactive protein (CRP), in adults with overweight or obesity compared to placebo.
If you have overweight or obesity, taking once-weekly semaglutide 2.4 mg significantly lowers your C-reactive protein (CRP), a key marker of systemic inflammation and cardiovascular risk. This benefit occurs alongside weight loss and is consistent regardless of your baseline BMI or diabetes status. The treatment involves a gradual dose escalation over 16 weeks to minimize side effects, followed by maintenance at 2.4 mg weekly for 68 weeks, combined with lifestyle changes.
In all trials, semaglutide 2.4 mg reduced CRP at week 68 versus placebo (estimated treatment difference [ETD; 95% CI] −44% [–49 to −39] in STEP 1, –39% [–46 to −30] in STEP 2, and –48% [–55 to −39] in STEP 3; all p < 0.05).
Why this rating
Based on three large, randomized, double-blind, placebo-controlled phase 3 trials (STEP 1, 2, 3) with consistent results.
Source
Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials
Subodh Verma et al. · EClinicalMedicine · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →